AbbVie Inc. (BIT:1ABBV)

Market Cap	294.56B
Revenue (ttm)	53.08B
Net Income (ttm)	3.84B
Shares Out	n/a
EPS (ttm)	2.16
PE Ratio	76.62
Forward PE	15.02
Dividend	4.29 (2.57%)
Ex-Dividend Date	Apr 14, 2025

Volume	125
Average Volume	20
Open	166.20
Previous Close	166.00
Day's Range	165.80 - 167.00
52-Week Range	149.00 - 202.55
Beta	n/a
RSI	54.49
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD